The intestinal barrier: a pivotal role in health, inflammation, and cancer
- PMID: 40086468
- DOI: 10.1016/S2468-1253(24)00390-X
The intestinal barrier: a pivotal role in health, inflammation, and cancer
Abstract
The intestinal barrier serves as a boundary between the mucosal immune system in the lamina propria and the external environment of the intestinal lumen, which contains a diverse array of microorganisms and ingested environmental factors, including pathogens, food antigens, toxins, and other foreign substances. This barrier has a central role in regulating the controlled interaction between luminal factors and the intestinal immune system. Disruptions of intestinal epithelial cells, which serve as a physical barrier, or the antimicrobial peptides and mucins they produce, which act as a chemical barrier, can lead to a leaky gut. In this state, the intestinal wall is unable to efficiently separate the intestinal flora and luminal contents from the intestinal immune system. The subsequent activation of the immune system has an important role in the pathogenesis of inflammatory bowel disease, as well as in metabolic dysfunction-associated steatohepatitis, primary sclerosing cholangitis, and colorectal cancer. Dysregulated intestinal barrier integrity has also been described in patients with chronic inflammatory diseases outside the gastrointestinal tract, including rheumatoid arthritis and neurodegenerative disorders. Mechanistic studies of barrier dysfunction have revealed that the subsequent local activation and systemic circulation of activated immune cells and the cytokines they secrete, as well as extracellular vesicles, promote proinflammatory processes within and outside the gastrointestinal tract. In this Review, we summarise these findings and highlight several new therapeutic concepts currently being developed that attempt to control inflammatory processes via direct or indirect modulation of intestinal barrier function.
Copyright © 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests The research of MFN and CB has been supported by the Interdisciplinary Center for Clinical Research (IZKF) Erlangen and the DFG TRR241 (projects C04 and A03), SFB1181, FOR2438, DFG Sachbeihilfe (IL-20 and STAT2 in inflammatory bowel disease [IBD]), and individual grants with the project numbers 418055832 and 510624836. Research in the Artis lab has been supported by the US National Institutes of Health (DK126871, AI151599, AI095466, AI095608, AI142213, AR070116, AI172027, and DK132244), Cure for IBD, Weill Cornell Medicine Jill Roberts Institute, the Sanders Family and the Rosanne H Silbermann Foundation. MFN has given lectures and served on advisory boards for Pentax, PPM, Novartis, Boehringer, AbbVie, MSD, J&J, Takeda, Lilly, and MonteRosa.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources